Plain-English translation of NCT06551207 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether fuquinitinib combined with cardonilizumab (an immunotherapy drug) and radiation therapy (SBRT) can help people with advanced colorectal cancer that no longer responds to standard treatments. You would be randomly assigned to receive either the three-treatment combination or fuquinitinib alone. The goal is to see if adding the immunotherapy and radiation helps patients live longer without their cancer growing.
People with advanced colorectal cancer often run out of standard treatment options, and their cancer continues to grow. Researchers believe combining this medication with an immunotherapy drug and targeted radiation might work better than the medication by itself to slow or stop cancer growth.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly for check-ins and blood work to monitor how the treatment is working and watch for side effects. If you are randomly selected for the combination group, you would take the medication by mouth and receive the immunotherapy drug as an infusion, along with a course of focused radiation therapy to specific areas of your cancer. The study team will track your cancer's response over at least 6 months to see if the treatment is helping.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China
Sponsor
Liu Huang
Enrollment target
~80 participants
Started
August 2024
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xianglin Yuan, PhD,MD
Liu Huang
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.